Evidence map›Paper›PMID 36383138›Full record

ReviewThe Analyst2023

Overview and considerations in bottom-up proteomics.

Rachel M Miller, Lloyd M Smith

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Analyst, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Proteomic Technology.Advances in experimental medicine and biology · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Observational
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rachel M MillerDepartment of Chemistry, University of Wisconsin-Madison, Madison, WI, USA. smith@chem.wisc.edu.
Lloyd M SmithDepartment of Chemistry, University of Wisconsin-Madison, Madison, WI, USA. smith@chem.wisc.edu.ORCID http://orcid.org/0000-0002-6652-8639

Funding

Sequence-specific Hybridization Capture to Reveal the lncRNA Interactome in Prostate CancerR01CA193481 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI DAVID F. JARRARD, Lloyd M Smith · 2015 to 2026
$3.4M
NCI NIH HHS R01 CA193481
6 · The paper itself

Abstract

Proteins are the key biological actors within cells, driving many biological processes integral to both healthy and diseased states. Understanding the depth of complexity represented within the proteome is crucial to our scientific understanding of cellular biology and to provide disease specific insights for clinical applications. Mass spectrometry-based proteomics is the premier method for proteome analysis, with the ability to both identify and quantify proteins. Although proteomics continues to grow as a robust field of bioanalytical chemistry, advances are still necessary to enable a more comprehensive view of the proteome. In this review, we provide a broad overview of mass spectrometry-based proteomics in general, and highlight four developing areas of bottom-up proteomics: (1) protein inference, (2) alternative proteases, (3) sample-specific databases and (4) post-translational modification discovery.

Indexed as

ProteomeProteomicsMass SpectrometryPeptide HydrolasesProtein Processing, Post-TranslationalPeptide HydrolasesProteome

Identifiers

PMID36383138
PMCPMC9898146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.